Methods and systems that remove impurities from phosphogypsum (PG), including from radium and heavy metal salts, and produce gypsum binders and products. In one embodiment, PG is reacted with a chloride solution in an acidic environment under mechanical manipulation and/or heat followed by galvanic and/or zeolite absorption removal of impurities.

Methods and systems that remove impurities from phosphogypsum (PG), including from radium and heavy metal salts, and produce gypsum binders and products. In one embodiment, PG is reacted with a chloride solution in an acidic environment under mechanical manipulation and/or heat followed by galvanic and/or zeolite absorption removal of impurities.

A method of manufacturing particles of UO.sub.2 for a porous matrix of a target for use in the manufacture of .sup.99Mo, comprising: infiltrating a solution of uranyl nitrate into a polymer template (62); either (i) introducing an alkali chemical to the uranyl nitrate infiltrated polymer template (64), causing precipitation of uranium oxide/hydroxide, and converting the uranium oxide/hydroxide to U.sub.3O.sub.8 (68) and concurrently removing the polymer template (70), by heating the infiltrated polymer template; or (ii) converting the uranyl nitrate to U.sub.3O.sub.8 (66) and concurrently removing the polymer template (74), by heating the infiltrated polymer template; and reducing the U.sub.3O.sub.8 to UO.sub.2 via heating in a reducing atmosphere (72).

The present invention relates to a particle or pharmaceutical composition comprising one, more particles or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

The present invention relates to a particle or pharmaceutical composition comprising one, more particles or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

A process for producing a titanium-molybdate material is provided. The process includes a step of reacting a metal molybdenum (Mo) material in a liquid medium with a first acid to provide a Mo composition and combining the Mo composition with a titanium source to provide a TiMo composition. The TiMo composition can be pH adjusted with a base to precipitate a plurality of TiMo particulates.

What is provided is stannous oxide having an -ray emission amount of 0.002 cph/cm.sup.2 or less after heating in an atmosphere at 100 C. for 6 hours. Tin containing lead as an impurity is dissolved in a sulfuric acid aqueous solution to prepare a tin sulfate aqueous solution, and lead sulfate is precipitated in the aqueous solution and removed. While stirring the tin sulfate aqueous solution from which lead sulfate has been removed, a lead nitrate aqueous solution containing lead having an -ray emission amount of 10 cph/cm.sup.2 or less is added to cause lead sulfate to be precipitated in the tin sulfate aqueous solution, and simultaneously the tin sulfate aqueous solution is circulated while removing the lead sulfate from the aqueous solution. A neutralizing agent is added to the tin sulfate aqueous solution to collect stannous oxide.